Chapman EM: History of the discovery and early use of radioactive iodine. JAMA. 1983, 250: 2042-2044. 10.1001/jama.250.15.2042.
Hagen F, Ouelette RP, Chapman EM: Comparison of high and low dosage levels of 131I in the treatment of thyrotoxicosis. N Engl J Med. 1967, 277: 559-62.
Cevallos JL, Hagen GA, Maloof F, Chapman EM: Low-dosage 131I therapy of thyrotoxicosis (diffuse goiters). N Engl J Med. 1974, 290: 141-3.
Ross DS, Daniels GH, De Stafano P, Maloof F, Ridgway EC: Use of adjunctive potassium iodide after radioactive iodine (131I) treatment of Graves' hyperthyroidism. J Clin Endocrinol Metab. 1983, 57: 250-3.
Glennon JA, Gordon ES, Sawin CT: Hypothyroidism after low-dose I131 treatment of hyperthyroidism. Ann Intern Med. 1972, 76: 721-3.
Saito S, Sakurada T, Yamamoto M, Yoshida K, Kaise K, Kaise N, Yoshinaga K: Long term results of radioiodine (131I) therapy in 331 patients with Graves' disease. Tokyo J Exp Med. 1980, 132: 1-10.
DeGroot LJ, Mangklabruks A, McCormick M: Comparison of RA 131I treatment protocols for Graves' disease. J Endocrinol Invest. 1990, 13: 111-118.
Chapman EM, Maloof F: The use of radioactive iodine in the diagnosis and treatment of hyperthyroidism: Ten years' experience. Medicine. 1955, 34: 261-
Blahd W, Hays MT: Graves' disease in the male. A review of 241 cases treated with an individually calculated dose of sodium iodide 131I. Arch Intern Med. 1972, 129: 33-40. 10.1001/archinte.129.1.33.
Bajnok L, Mezosi E, Nagy E, Szabo J, Sztojka I, Varga J, Galuska L, Leovey A: Calculation of the radioiodine dose for the treatment of Graves' hyperthyroidism: is more than seven-thousand rad target dose necessary?. Thyroid. 1999, 9: 865-9.
Wise PH, Burnet RB, Ahmad A, Harding PE: Intentional radioiodine ablation in Graves' disease. Lancet. 1975, 2: 1231-3. 10.1016/S0140-6736(75)92071-1.
Rajashekharrao B, Nair N: Thyroidal absorbed dose from a standard five-millicurie Iodine-131 (185MBq) dose for thyrotoxicosis: Cure can occur with less than the conventional 7000 rads. J Nucl Med. 1991, 32: 364-365.
Hays MT: Hypothyroidism following iodine-131 therapy. J Nucl Med. 1982, 23: 176-179.
Okada S: Radiation Biochemistry. Vol 1.Academic Press: New York, NY;. 1970, 247-285.
Doniach I: In Green MA, Solomon DH (eds) Handbook of physiology. Section 7:Endocrinology Vol III. Thyroid. American Physiological Society, Washington DC,. 1974
Al-Hindawi AY, Wilson GM: The effect of irradiation on the function and survival of rat thyroid cells. Clin Sci. 1965, 28: 555-571.
Walinder G, Sjoden AM: Effect of irradiation on thyroid growth in mouse foetuses and goitrogen challenged adult mice. Acta Radiol Ther Phys Biol. 1971, 10: 579-592.
Becker DV, McConahey WM, Dobyns BM, Tomkins E, Sheline GE, Workman JB: The results of radioiodine treatment of hyperthyroidism. A preliminary report of the Thyrotoxicosis Therapy Follow-up Study. In Further Advances in Thyroid Research, Vol 1, Fellinger K and Hofer R (eds) Vienna. 1971, 607-
Malone JF, Cullen MJ: Two mechanisms for hypothyroidism after 131I therapy. Lancet. 1976, 2: 73-75. 10.1016/S0140-6736(76)92290-X.
Alevizaki CC, Alevizaki-Harhalaki MC, Ikkos DG: Radioiodine-131 treatment of thyrotoxicosis: dose required for and some factors affecting the early induction of hypothyroidism. Eur J Nucl Med. 1985, 10: 450-454.
Dunn JT, Chapman EM: Rising Incidence of Hypothyroidism after Radioactive-Iodine Therapy in Thyrotoxicosis. N Engl J Med. 1964, 271: 1037-1042.
Nygaard B, Hegedus L, Gervil M, Hjalgrim H, Hansen BM, Soe-Jensen P, Hansen JM: Influence of compensated radioiodine therapy on thyroid volume and incidence of hypothyroidism in Graves disease. J Intern Med. 1995, 238: 491-497.
Goolden AWG, Stewart JSW: Long-term results from graded low dose radioactive iodine therapy for thyrotoxicosis. Clinical Endocrinology(Oxf). 1986, 24: 217-222.
Verelst J, Bonnyns M, Glinoer D: Radioiodine therapy in voluminous multinodular non-toxic goitre. Acta Endocrinologica (Copenh). 1990, 122: 417-421.
Loevinger R, Holt JG, Hine GJ: Internally administered isotopes in radiation dosimetry. Hine GJ, Brownell GL (eds), Acad Press New York. 1956, 801-875.
Smith RN, Wilson GM: Clinical trials of different doses of 131I treatment of thyrotoxicosis. Br Med J. 1967, 1: 129-132.
Kendall-Taylor P, Keir MJ, Ross WM: Ablative radioiodine therapy for hyperthyroidism: Long-term follow-up study. Br Med J. 1984, 289: 361-363.
Blomfield GW, Jones JC, Macgregor AG, Miller H, Wayne EJ, Weetch RS: Treatment of thyrotoxicosis with radioactive iodine. Review of 140 cases. Br Med J. 1955, 1: 1223-1229.
Berg GE, Michanek AM, Holmberg EC, Fink M: Iodine-131 treatment of hyperthyroidism: Significance of effective half-life measurements. J Nucl Med. 1996, 37: 228-232.
Blahd Wh, Hays MT: Graves disease in the male. Arch Intern Med. 1972, 129: 33-40. 10.1001/archinte.129.1.33.
Clerc J, Izembart M, Dagousset F, Jais JP, Heshmati HM, Chevalier A, Leger AF, Barritault L: Influence of dose selection on absorbed dose profiles in radioiodine treatment of diffuse toxic goiters in patients receiving or not receiving carbimazole. J Nucl Med. 1993, 34: 387-93.
Nagayama Y, Ashizawa K, Matsuo K, Inoue S, Harakawa S, Hirayu H, Yamashita S, Izumi M, Nagataki S: Radioiodine (131I) therapy of Graves' disease: Use of the new high resolutional ultrasonic scanner for the determination of the accurate weight of the thyroid gland. Endocrinol Jpn. 1989, 36: 359-365.
Rapoport B, Caplan R, DeGroot L: Low-dose sodium iodide 131I therapy in Graves' disease. JAMA. 1973, 224: 1610-3. 10.1001/jama.224.12.1610.
Hegedus L, Hansen JEM, Veiergang D, Karstrup S: Thyroid size and goitre frequency in hyperthyroidism. Dan Med Bull. 1987, 34: 121-123.
Peters H, Fischer C, Bogner U, Reiners C, Schleusener H: Radioiodine therapy of Graves' hyperthyroidism: Standard vs. Calculated 131 iodine activity. Results from a prospective, randomized, multicentre study. European J Clin Invest. 1995, 25: 186-193.
Willemsen UF, Knesewitsch P, Kreisig T, Pickardt CR, Kirsch CM: Functional results of radioiodine therapy with a 300 Gy absorbed dose in Graves' disease. Eur J Nucl Med. 1993, 20: 1051-1055.
Kung AWC, Pun KK, Lam KSL, Choi P, Wang C, Yeung RTT: Long-term results following 131I treatment for Graves disease in Hong Kong chinese – Discriminant factors predicting hypothyroidism. Quart J Med. 1990, 76: 961-967.
Blomfield GW, Eckert H, Fisher M, Miller H, Munro DS, Wilson GM: Treatment of thyrotoxicosis with 131I. A review of 500 cases. Br Med J. 1959, 1: 63-74.
Tsuruta M, Nagayama Y, Yokoyama N, Izumi M, Nagataki S: Long term followup studies on iodine-131 treatment of hyperthyroid Graves' disease based on measurement of thyroid volume by ultrasonography. Ann Nucl Med. 1993, 7: 193-197.
Rapoport B, Caplan R, DeGroot LJ: Low-dose sodium iodide 131I therapy in Graves disease. JAMA. 1973, 224: 1610-1613. 10.1001/jama.224.12.1610.
Flower MA, Al-Saadi A, Harmer CL, McCready VR, Ott RJ: Dose-response study on thyrotoxic patients undergoing positron emission tomography and radioiodine therapy. Eur J Nucl Med. 1994, 21: 531-6.
Pfeilschifter J, Elser H, Haufe S, Ziegler R, Georgi P: Impact of pre-treatment variables on the outcome of standardized 131I therapy with 150 Gray in Graves' disease. Nuklearmedizin. 1997, 36: 81-86.
Green M, Wilson GM: Thyrotoxicosis treated by surgery or Iodine-131 with special reference to the development of hypothyroidism. Br Med J. 1964, 1: 1005-1010.
Sabri O, Zimny M, Schulz G, Schreckenberger M, Reinartz P, Willmes K, Buell U: Success rate of radioiodine therapy in Graves' disease: the influence of thyrostatic medication. J Clin Endocrinol Metab. 1999, 84: 1229-33. 10.1210/jc.84.4.1229.
Moser E, Pickardt CR, Mann K, Engelhardt D, Kirsch CM, Knesewitsch P, Tatsch K, Kreisig T, Kurz C, Saller B: Results of radioiodine treatment of patients with immunogenic and non-immunogenic hyperthyroidism using different focal doses. Nuklearmedizin. 1988, 27: 98-104.
Nofal MM, Beierwaltes WH, Patno ME: Treatment of hyperthyroidism with sodium iodide I 131. JAMA. 1966, 197: 87-92.
de Bruin TW, Croon CD, de Klerk JM, van Isselt JW: Standardized radioiodine therapy in Graves' disease: the persistent effect of thyroid weight and radioiodine uptake on outcome. J Intern Med. 1994, 236: 507-513.
Jarlov AE, Hegedus L, Kristensen LO, Nygaard B, Hansen JM: Is calculation of the dose in radioiodine therapy of hyperthyroidism worthwhile?. Clin Endocrinol Oxf. 1995, 43: 325-329.
Chen JY, Huang HS, Huang MJ, Lin JD, Juang JH, Huang BY, Wang PW, Liu RT: Outcome following radioactive iodine therapy in Graves' disease. Chang Keng I Hsueh. 1990, 13: 258-267.
Bliddal H, Hansen JM, Rogowski P, Johansen K, Friis T, Siersbaek-Nielsen K: 131I treatment of diffuse and nodular toxic goitre with or without antithyroid agents. Acta Endocrinologica. 1982, 99: 517-521.
Kalk WJ, Durbach D, Kantor S, Levin J: Very low doses of radioiodine for hyperthyroidism. Failure to prevent a high incidence of early hypothyroidism. South African Med J. 1970, 44: 479-482.
Chiovato L, Fiore E, Vitti P, Rocchi R, Rago T, Dokic D, Latrofa F, Mammoli C, Lippi F, Ceccarelli C, Pinchera A: Outcome of thyroid function in Graves' patients treated with radioiodine: role of thyroid-stimulating and thyrotropin-blocking antibodies and of radioiodine-induced thyroid damage. J Clin Endocrinol Metab. 1998, 83: 40-6. 10.1210/jc.83.1.40.
Imseis RE, Vanmiddlesworth L, Massie JD, Bush AJ, Vanmiddlesworth NR: Pretreatment with propylthiouracil but not methimazole reduces the therapeutic efficacy of iodine-131 in hyperthyroidism. J Clin Endocrinol Metab. 1998, 83: 685-7. 10.1210/jc.83.2.685.
Eriksson E, Eriksson K, Wahlberg P: Treatment of hyperthyroidism with standard doses of radioiodine aiming at ablation. Acta Medica Scand. 1985, 217: 55-60.
Lowdell CP, Dobbs HJ, Spathis GS, McCready VR, Harmer CL: Low-dose 131I in treatment of Graves' disease. J Royal Soc Med. 1985, 78: 197-202.
Nordyke RA, Gilbert FI: Optimal iodine-131 dose for eliminating hyperthyroidism in Graves' disease. J Nucl Med. 1991, 32: 411-416.
Watson AB, Brownlie BEW, Frampton CM, Turner JG, Rogers TGH: Outcome following standardized 185 MBq dose 131I therapy for Graves' disease. Clinical Endocrinology(Oxf). 1988, 28: 487-496.
Turner J, Sadler W, Brownlie B, Rogers T: Radioiodine therapy for Graves' disease: Multivariate analysis of pretreatment parameters for early outcome. Eur J Nucl Med. 1985, 11: 191-193.
Safe AF, Maxwell RT: Efficiency of treatment and monitoring of ablative radio iodine therapy for hyperthyroidism: A DGH centre study. Br J Clin Prac. 1990, 44: 393-395.
Danaci M, Feek CM, Notghi A, Merrick MV, Padfield PL, Edwards RW: 131-I radioiodine therapy for hyperthyroidism in patients with Graves' disease, uninodular goitre and multinodular goitre. N Z Med J. 1988, 101: 784-6.
Johnson JK: Outcome of treating thyrotoxic patients with a standard dose of radioactive iodine. Scott Med J. 1993, 38: 142-4.
Child DF, Mughni MAS, Hudson P, Williams CP, Harvey JN: Hyperthyroidism and radio-iodine therapy in a district general hospital. J R Soc Med. 1994, 87: 578-580.
Bringmann IM, van Leeuwen BL, Hennemann G, Beckett GJ, Toft AD: Outcome of treatment of hyperthyroidism. J Endocrinol Invest. 1999, 22: 250-6.
Von Hofe SE, Dorfman SG, Carretta RF, Young RL: The increasing incidence of hypothyroidism within one year after radioiodine therapy for toxic diffuse goiter. J Nucl Med. 1978, 19: 180-184.
Sridama V, McCormick M, Kaplan EL, Fauchet R, DeGroot LJ: Long-term follow-up study of compensated low-dose 131I therapy for Graves' disease. N Engl J Med. 1984, 311: 426-432.
Roudebush CP, Hoye KE, DeGroot LJ: Compensated low-dose 131I therapy of Graves' disease. Ann Intern Med. 1977, 87: 441-443.
Haase A, Bahre M, Lauer I, Meller B, Richter E: Radioiodine therapy in Graves' hyperthyroidism: determination of individual optimum target dose. Exp Clin Endocrinol Diabetes. 2000, 108: 133-7. 10.1055/s-2000-5807.
Zaini A, Khir A, Doi SAR, Chan SP, Paramsothy M, Khoo BH: Results of long-term follow-up after compensated fixed-dose therapy for thyrotoxicosis. J Int Med Res. 1992, 20: 279-288.
Macgregor AG: Simplified radioactive iodine therapy. Br Med J. 1957, 2: 492-495.
Delange F, Bastani S, BenMiloud M: Definitions of endemic goiter and cretinism, classification of goiter size and severity of endemias, and survey techniques. In: Dunn JT, Pretell EA, Daza CH, Viteri FE, eds. Towards the eradication of endemic goiter, cretinism, and iodine deficiency. Washington, DC: Pan American Health Organization,. 1986, p373-76.
Stanbury JB, Ermans AM, Hetzel BS, Pretell EA, Querido A: Endemic goitre and cretinism: Public health significance and prevention. WHO Chronicle. 1974, 28: 220-228.
Catargi B, Leprat F, Guyot M, Valli N, Ducassou D, Tabarin A: Optimized radioiodine therapy of Graves' disease: Analysis the delivered dose and of other possible factors affecting outcome. Eur J Endocrinol. 1999, 141: 117-121.
Kelsy MP, Haines SF, Keating FR: Radioiodine in the study and treatment of thyroid disease. A review. J Clin Endocrinology. 1949, 9: 171-210.
Oddie TH: Dosage from radioisotopes uniformly distributed within a sphere. Br J Radiol. 1951, 24: 333-336.
Editorial: Protean symptomatology of myxoedema. Br Med J. 1970, 3: 61-62.
Berghout A, Wiersinga WM, Smits NJ, Touber JL: The value of thyroid volume measured by ultrasonography in the diagnosis of goitre. Clin Endocrinol Oxf . 1988, 28: 409-414.
Hsiao YL, Chang TC: Ultrasound evaluation of thyroid abnormalities and volume in Chinese adults without palpable thyroid glands. J Formos Med Assoc. 1994, 93: 140-4.